SUVEN Life Sciences Ltd

News Release

Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual Meeting, SFN-2007 at San Diego, USA

HYDERABAD, INDIA (Nov 5th , 2007) – *Several data presentations from Suven's own portfolio of investigational new chemical entities (NCEs) were presented at Neuroscience 2007 meeting being held at San Diego, USA from Nov 3-7.* *Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro Scientists from all over the world covering all the major Pharma and Academic research Institutions would attend this meeting.*

Suven is presenting new data of their New Chemical Entities (NCE's) in the five (5) promising areas of neuroscience viz. Alzheimer's, Schizophrenia, Parkinson, Sleep and Obesity diseases for which Suven was granted 9 product patents (2 from EU, 3 from India, 2 from Australia and 2 from New Zealand). These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programs in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients. All these programs belong to Suven's in house drug discovery program and does not involve any partner or collaborator.

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven's discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven's CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders, Sleep, Neurodegeneration and Obesity through CNS targets.

Suven Life Sciences is a Hyderabad based Life Sciences Company a **Collaborative Research Partner (CRP)** since 2006 in **Drug Discovery** for global pharma major is a pioneer in **Contract Research and Manufacturing Services (CRAMS)** since 1995 and **Drug Discovery Development Support Services (DDDSS)** since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 255 professionals with the state of the art infrastructure for Drug Discovery and development activities and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at **http://www.suven.com**

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;